Unified regulatory standards and pharmacovigilance harmonization are critical to enabling global pharmaceutical firms to operate more safely and efficiently. By normalizing the reporting of clinical data, stakeholders can minimize risks, improve market conditions, support early access to products, promote competition and efficiency, and reduce the unnecessary duplication of clinical testing. Multiple regulatory agencies, including the…